CXL146

01/01/2020 - "In the present study, we elucidated its selective mechanism in four MDR cancer cell lines with one lead candidate (CXL146). "
01/01/2020 - "Cytotoxicity results confirmed the selective cytotoxicity of CXL146 toward the MDR cancer cell lines. "
01/01/2020 - "Further characterization indicates that CXL146 and standard therapies complementarily target different populations of cancer cells, supporting the potential of CXL146 to overcome multidrug resistance in cancer treatment."
01/01/2020 - "Therefore, further exploration of CXL146 as a novel therapy in treating MDR cancer cells is warranted. "
08/01/2020 - "Correction to "CXL146, a Novel 4H-Chromene Derivative, Targets GRP78 to Selectively Eliminate Multidrug-Resistant Cancer Cells"."

01/01/2020 - "Using human leukemia (HL) 60/mitoxantrone (MX) 2 cell line as the model, we demonstrated that CXL146 treatment activated the unfolded protein response (UPR); as evidenced by the activation of inositol-requiring enzyme 1α, protein kinase R-like ER kinase, and activating transcription factor 6. CXL146-induced UPR activation led to a series of downstream events, including extracellular signal-regulated kinase 1/2 and c-Jun N-terminal kinase activation, which contributed to CXL146-induced apoptosis. "